Parkinson disease, cancer, and LRRK2: Causation or association?

Neurology

Volumn 78, Issue 11, 2012, Pages 772-773

  Bandmann, Oliver ^a   Cookson, Mark R ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DEATH; CELL SURVIVAL; COLON CANCER; DISEASE PREDISPOSITION; EDITORIAL; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE TARGETING; HEREDITY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; FEMALE; GENETICS; MALE; NEOPLASM; NOTE;

FEMALE; HUMANS; MALE; NEOPLASMS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84859931252     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318249f744     Document Type: Editorial

References (11)

1. Plun-Favreau H, Lewis PA, Hardy J, Miguel Martins L, Wood NW. Cancer and neurodegeneration: Between the devil and the deep blue sea. PLoS Genet 2010;6: E1001257.
2. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: A systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
3. Lo RY, Tanner CM, van Den Eeden SK, Albers KB, Leimpeter AD, Nelson L. Comorbid cancer in Parkinson's disease. Mov Disord 2010;25:1809-1817.
4. Paisan-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology 2010;75:1653-1655.
5. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's Disease. Nat Rev Neurosci 2010; 11:791-797.
6. Inzelberg R, Cohen OS, Aharon-Peretz J, et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012; 78:781-786.
7. Saunders-Pullman R, Barrett MJ, Stanley KM, et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson's disease. Mov Disord 2010;25:2536-2545.
8. Strongosky AJ, Farrer M, Wszolek ZK. Are Parkinson disease patients protected from some but not all cancers? Neurology 2008;71:1650-1651.
9. Marin I, Egmond WN, van Haastert PJM. The Roco protein family: A functional perspective. FASEB J 2008;22: 3103-3110.
10. Looyenga BD, Furge KA, Dykema, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signalling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci 2011;108: 1439-1444.
11. Ye J, Pavlicek A, Lunney EA, Rejto PA, Teng C-H. Statistical method on non-random clustering with application to somatic mutations in cancer. BMC Bioinformatics 2010;11:11.